[Modification of the immune reaction by antigen-immunosuppressive-agent conjugates. II. Immunogenicity of antigen-immunosuppressive-agent conjugates].
The maintenance of specific immunogenicity of carrier proteins is a necessary condition for the successful use of antigen-immunosuppressive agent-conjugates (AIC) for an antigen specific suppression of the immune response. The experimental results indicate that, in spite of the binding of 6-mercaptopurine (6-MP) and toluyl (T) to bovine gamma globulin (BGG) and human serum albumin (HSA), the carrier specific immunogenicity is not significantly altered. The intradermal application of 6-MP-BGG and T-BGG emulsified with complete Freund's adjuvant in guinea pigs results, in all cases, in a well detectable anti BGG hemagglutination and precipitation titer. This kind of immunization leads also to a formation of anti 6-mercaptopurine and anti new antigen determinants (NAD's) antibodies.
D000818:Animals; D000917:Antibody Formation / Q000187:drug effects*; D000937:Antigen-Antibody Reactions / Q000187:drug effects; D000941:Antigens; D002352:Carrier Proteins / Q000276:immunology* / Q000494:pharmacology; D002417:Cattle; D000939:Epitopes; D006384:Hemagglutination / Q000187:drug effects; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D008214:Lymphocytes / Q000276:immunology; D015122:Mercaptopurine / Q000494:pharmacology*; D011485:Protein Binding / Q000187:drug effects
D000941:Antigens; D002352:Carrier Proteins; D000939:Epitopes; D007166:Immunosuppressive Agents; D015122:Mercaptopurine
Die Beeinflussung von Immunreaktionen durch Antigen-Immunsuppressivum-Konjugate. II. Immunogenität von Trägerprotein-Konjugaten